Marching Forward in Atopic Dermatitis

Dinner will be provided.

This activity is provided by Integritas Communications.

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

The Non-CME Corporate Forum content and views expressed therein do not necessarily reflect the views, policies or position of the American College of Allergy, Asthma & Immunology.

Target Audience

The educational design of this activity addresses the needs of allergists/clinical immunologists and other clinicians who treat patients with moderate-to-severe atopic dermatitis.

Statement of Need/Program Overview

Atopic dermatitis is a common, chronic inflammatory disease that manifests primarily in the skin, although research has uncovered potentially deleterious effects in other organ systems throughout the body.^1,2 The disease-related physical and biopsychosocial burdens of this condition can have a substantial effect on patient and parent/caregiver quality of life.^3,4 Furthermore, people with atopic dermatitis have a higher likelihood of developing atopic comorbidities, also known as the atopic march.⁵ A better understanding of atopic dermatitis disease etiology has resulted in new insights into disease characterization and led to the development of targeted therapies.^6-8 As a result, the first biologic therapy is now FDA-approved to treat both adolescent and adult patients with moderate-to-severe atopic dermatitis, with other novel therapies in late-stage clinical development.^8-11 In this Interactive Exchange™ program, two experts in atopic dermatitis will review the pathophysiologic underpinnings of atopic dermatitis, new insights into disease characterization (including emerging research in distinct phenotypes and endotypes), common atopic and nonatopic comorbidities, and recommended management strategies for adolescents and adults with more severe disease.^5,12-15 In the final segment of the program, attendees will select a case study for discussion, giving the faculty an opportunity to summarize the newly presented information in the context of a practical, real-world scenario.

References

1. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015:66(suppl 1):8-16.
2. Brunner PM, et al. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J Invest Dermatol. 2017;137(1):18-25.
3. Carroll CL, et al. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol. 2005;22(3):192-199.
4. Drucker AM, et al. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26-30.
5. Paller AS, et al. The atopic march and atopic multimorbidity: many trajectories, many pathways. J Allergy Clin Immunol. 2019;143(1):46-55.
6. Mansouri Y, Guttman-Yassky E. Immune pathways in atopic dermatitis, and definition of biomarkers through broad and targeted therapeutics. J Clin Med. 2015;4(5):858-873.
7. Gandhi NA, et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50.
8. Renert-Yuval Y, Guttman-Yassky E. What’s new in atopic dermatitis. Dermatol Clin. 2019;37(2):205-213.
9. Wollenberg A, et al. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2019;143(1):135-141.
10. Simpson EL, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348.
11. Simpson EL, et al. Dupilumab efficacy and safety in adolescents with moderate-to-severe atopic dermatitis: results from a multicenter, randomized, placebo-controlled, double-blind, parallel-group, phase 3 study. Presented at the 27th EADV Congress; September 12-16, 2018; Paris, France. Poster 4640.
12. Czarnowicki T, et al. Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol. 2019;143(1):1-11.
13. Sandhu JK, et al. Association between atopic dermatitis and suicidality: a systemic review and meta-analysis. JAMA Dermatol. 2019;155(2):178-187.
14. Brunner PM, et al. Increasing comorbidities suggset that atopic dermatitis is a systemic disorder. J Invest Dermatol. 2017;137(1):18-25.
15. Ariëns LFM, et al. Dupilumab in atopic dermatitis: rationale, latest evidence and place in therapy. Ther Adv Chronic Dis. 2018;9(9):159-170.

Educational Objectives

Upon completion of this activity, participants will be better able to do the following:

1. Discuss clinically relevant pathophysiologic processes in atopic dermatitis
2. Evaluate patients with moderate-to-severe atopic dermatitis for disease severity, comorbid conditions, and other biopsychosocial consequences
3. Describe the clinical profiles and prescribing considerations for targeted therapies for atopic dermatitis
4. Tailor therapy regimens for patients with moderate-to-severe atopic dermatitis based on ongoing symptoms, burdens, comorbidities, and shared clinical decision-making

Program Agenda

7:00 PM – 7:30 PM: Registration and Dinner
7:30 PM – 7:40 PM: Preactivity Questionnaire and Faculty Introductions
7:40 PM – 7:55 PM: Atopic Dermatitis Pathophysiology
7:55 PM – 8:15 PM: Clinical Characteristics and Patient Assessment
8:15 PM – 8:30 PM: Personalizing Therapy for Patients With Moderate-to-Severe Atopic Dermatitis
8:30 PM – 8:45 PM: Choose-a-Case^TM
8:45 PM – 9:00 PM: Postactivity Questionnaire and Question & Answer

Americans with Disabilities Act

Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Nora Eldasher prior to the live event at neldasher@integritasgrp.com.

There is no registration fee for attending this program; however, seating is limited. Preregistration does not guarantee seating. We recommend arriving at the symposium location early.